Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

by Vandana Singh, Benzinga Editor

February 23, 2021 11:33 AM | 1 min read | Make a Comment

Health Canada has approved Sanofi’s SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT is also approved in Canada to treat adult patients with severe chronic rhinosinusitis with nasal polyposis and for the treatment of severe asthma in patients 12 years and older.
Also, both companies announced FDA approval of immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer.
Price Action: SNY is up 0.2% at $46.47, while REGN is down 2.3% at $449.8 in market trading hours on last check Tuesday.

Posted In: Biotech News Health Care FDA General atopic dermatitis Health Canada

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.